Caring Innovation: softgel capsules

Endocrinology, the study of the body’s hormone-producing glands, plays a critical role in managing many chronic conditions, including one of the most common endocrine disorders—hypothyroidism. Affecting nearly 5% of Americans over the age of 12, hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone.1 Left untreated, it can impact nearly every system in the body, leading to fatigue, weight gain, depression, and cognitive challenges.

IBSA USA’s parent company, IBSA (Institut Biochimique SA) is a leading, multinational pharmaceutical company engaged in 10 therapeutic areas with a mission to deliver solutions that are increasingly aligned with people’s needs. The company has made endocrinology - especially thyroid disorders - a strategic priority.

IBSA’s deep expertise in endocrinology reflects a broader commitment to improving how hormonal conditions are understood, managed, and treated. The company actively contributes to medical education and professional engagement, supporting clinicians and researchers in advancing endocrine care.

Guided by its philosophy—“striving to develop drugs in the best form”—IBSA invests in advancing delivery technologies and providing treatments that address challenges patients may face with traditional treatment options – whether through improved dosing precision, tolerability, or usability.

The standard treatment for hypothyroidism, replaces the hormone, thyroxine which is normally produced by the thyroid. IBSA USA markets unique treatments for hypothyroidism —including liquid and softgel capsule options with the same active ingredient of the standard treatment.

A comprehensive patient-based survey found that nearly half of patients taking traditional thyroid medicines have conditions that can negatively affect how well their medicine might work.2 Patients often face challenges with absorption, consistency, and daily adherence—factors that can significantly affect treatment outcomes.

To address these challenges, IBSA USA’s therapies for hypothyroidism are designed with patient tolerability and dosing consistency in mind. We aim to develop products that address the specific needs of those with absorption challenges or ingredient sensitivities.

As a leading provider of therapies for hypothyroidism, IBSA is committed to staying at the forefront—investing in research, engaging with the endocrine community, advancing drug technologies, and always keeping patients at the center of care.

IBSA: A Leader in Endocrinology